Literature DB >> 15871918

Susceptibility of Borrelia afzelii strains to antimicrobial agents.

Eva Ruzić-Sabljić1, Tjasa Podreka, Vera Maraspin, Franc Strle.   

Abstract

The aim of the present study was to determine the susceptibility of Borrelia afzelii strains to antibiotics, and to test the hypothesis that persistence of borrelia in skin, after therapy, is a consequence of resistance to the antibiotic used for treatment. Ten B. afzelii strains isolated from skin of seven adult patients (two with acrodermatitis chronica atrophicans, five with erythema migrans) were studied. In three patients B. afzelii was isolated from erythema migrans lesion before antibiotic therapy and 2-3 months after treatment with cefuroxime axetil (two patients) or with ceftriaxone (one patient). MICs and MBCs for amoxicillin, azithromycin, ceftriaxone, cefuroxime, doxycycline and amikacin were measured. There was total resistance to amikacin but isolates were susceptible to all other antibiotics except one isolate that was resistant to cefuroxime, MIC > 4 mg/L. Comparison of MBC values after 3 and 6 weeks' incubation revealed comparable results for azithromycin and ceftriaxone while for amoxicillin, cefuroxime and doxycycline, some differences were found. In one of the patients from whom there were borrelia isolated before and after treatment with cefuroxime axetil, both isolates were resistant to cefuroxime. In the other two patients, the paired isolates were susceptible to the antibiotic used for therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15871918     DOI: 10.1016/j.ijantimicag.2005.02.007

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  6 in total

1.  In Vitro Susceptibility of Treponema pallidum subsp. pallidum to Doxycycline.

Authors:  Diane G Edmondson; Gary P Wormser; Steven J Norris
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 2.  Antimicrobial susceptibility of Borrelia burgdorferi sensu lato: what we know, what we don't know, and what we need to know.

Authors:  Klaus-Peter Hunfeld; Volker Brade
Journal:  Wien Klin Wochenschr       Date:  2006-11       Impact factor: 1.704

3.  In Vitro Susceptibility of the Relapsing-Fever Spirochete Borrelia miyamotoi to Antimicrobial Agents.

Authors:  Joris Koetsveld; Ronald O P Draga; Alex Wagemakers; Annemijn Manger; Anneke Oei; Caroline E Visser; Joppe W Hovius
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 4.  Genetic Manipulation of Borrelia.

Authors:  Patricia A Rosa; Mollie W Jewett
Journal:  Curr Issues Mol Biol       Date:  2020-12-10       Impact factor: 2.081

5.  Comparison of effectiveness of cefovecin, doxycycline, and amoxicillin for the treatment of experimentally induced early Lyme borreliosis in dogs.

Authors:  Bettina Wagner; John Johnson; David Garcia-Tapia; Nicole Honsberger; Vickie King; Catherine Strietzel; John M Hardham; Thomas J Heinz; Richard T Marconi; Patrick F M Meeus
Journal:  BMC Vet Res       Date:  2015-07-25       Impact factor: 2.741

6.  Cutaneous Lyme borreliosis: Guideline of the German Dermatology Society.

Authors:  Heidelore Hofmann; Volker Fingerle; Klaus-Peter Hunfeld; Hans-Iko Huppertz; Andreas Krause; Sebastian Rauer; Bernhard Ruf
Journal:  Ger Med Sci       Date:  2017-09-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.